Literature DB >> 18084301

Modification of kidney barrier function by the urokinase receptor.

Changli Wei1, Clemens C Möller, Mehmet M Altintas, Jing Li, Karin Schwarz, Serena Zacchigna, Liang Xie, Anna Henger, Holger Schmid, Maria P Rastaldi, Peter Cowan, Matthias Kretzler, Roberto Parrilla, Moïse Bendayan, Vineet Gupta, Boris Nikolic, Raghu Kalluri, Peter Carmeliet, Peter Mundel, Jochen Reiser.   

Abstract

Podocyte dysfunction, represented by foot process effacement and proteinuria, is often the starting point for progressive kidney disease. Therapies aimed at the cellular level of the disease are currently not available. Here we show that induction of urokinase receptor (uPAR) signaling in podocytes leads to foot process effacement and urinary protein loss via a mechanism that includes lipid-dependent activation of alphavbeta3 integrin. Mice lacking uPAR (Plaur-/-) are protected from lipopolysaccharide (LPS)-mediated proteinuria but develop disease after expression of a constitutively active beta3 integrin. Gene transfer studies reveal a prerequisite for uPAR expression in podocytes, but not in endothelial cells, for the development of LPS-mediated proteinuria. Mechanistically, uPAR is required to activate alphavbeta3 integrin in podocytes, promoting cell motility and activation of the small GTPases Cdc42 and Rac1. Blockade of alphavbeta3 integrin reduces podocyte motility in vitro and lowers proteinuria in mice. Our findings show a physiological role for uPAR signaling in the regulation of kidney permeability.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18084301     DOI: 10.1038/nm1696

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  262 in total

1.  Kindlin-2 Association with Rho GDP-Dissociation Inhibitor α Suppresses Rac1 Activation and Podocyte Injury.

Authors:  Ying Sun; Chen Guo; Ping Ma; Yumei Lai; Fan Yang; Jun Cai; Zhehao Cheng; Kuo Zhang; Zhongzhen Liu; Yeteng Tian; Yue Sheng; Ruijun Tian; Yi Deng; Guozhi Xiao; Chuanyue Wu
Journal:  J Am Soc Nephrol       Date:  2017-08-03       Impact factor: 10.121

Review 2.  The podocyte cytoskeleton--key to a functioning glomerulus in health and disease.

Authors:  Gavin I Welsh; Moin A Saleem
Journal:  Nat Rev Nephrol       Date:  2011-10-25       Impact factor: 28.314

3.  In vivo electroporation and non-protein based screening assays to identify antibodies against native protein conformations.

Authors:  Pirouz Daftarian; Raquibul Chowdhury; Philip Ames; Changli Wei; Alan D King; Juan Pablo de Rivero Vaccari; Lloye Dillon; Justin Price; Howard Leung; Brittany Ashlock; Enrique Mesri; Victor Perez; Stephan Züchner; Jochen Reiser; Vance Lemmon; Robert W Keane
Journal:  Hybridoma (Larchmt)       Date:  2011-10

4.  Filtering new facts about kidney disease.

Authors:  Jochen Reiser
Journal:  Nat Med       Date:  2011-01       Impact factor: 53.440

5.  High molecular weight kininogen binds phosphatidylserine and opsonizes urokinase plasminogen activator receptor-mediated efferocytosis.

Authors:  Aizhen Yang; Jihong Dai; Zhanli Xie; Robert W Colman; Qingyu Wu; Raymond B Birge; Yi Wu
Journal:  J Immunol       Date:  2014-03-31       Impact factor: 5.422

6.  TNFα pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and β3 integrin activation.

Authors:  Martin Bitzan; Sima Babayeva; Anil Vasudevan; Paul Goodyer; Elena Torban
Journal:  Pediatr Nephrol       Date:  2012-04-27       Impact factor: 3.714

Review 7.  Principles of separation: indications and therapeutic targets for plasma exchange.

Authors:  Mark E Williams; Rasheed A Balogun
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 8.237

8.  Is there clinical value in measuring suPAR levels in FSGS?

Authors:  Sanja Sever; Howard Trachtman; Changli Wei; Jochen Reiser
Journal:  Clin J Am Soc Nephrol       Date:  2013-07-25       Impact factor: 8.237

Review 9.  Extrarenal determinants of kidney filter function.

Authors:  Eunsil Hahm; Vasil Peev; Jochen Reiser
Journal:  Cell Tissue Res       Date:  2017-05-30       Impact factor: 5.249

Review 10.  Therapeutic targets in focal and segmental glomerulosclerosis.

Authors:  Peter J Lavin; Rasheed Gbadegesin; Tirupapuliyur V Damodaran; Michelle P Winn
Journal:  Curr Opin Nephrol Hypertens       Date:  2008-07       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.